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Abstract
Background: A loss of heterozygosity (LOH) represents a unilateral chromosomal loss that
reduces the dose of highly repetitive Alu, L1, and LTR retroelements. The aim of this study was to
determine if the LOH events can affect the spread of retroelement methylation in the 5'-end
transitional area between the CpG islands and their nearest retroelements.
Methods: The 5'-transitional area of all human genes (22,297) was measured according to the
nearest retroelements to the transcription start sites. For 50 gastric cancer specimens, the level of
LOH events on eight cancer-associated chromosomes was estimated using the microsatellite
markers, and the 5'-transitional CpGs of 20 selected genes were examined by methylation analysis
using the bisulfite-modified DNA.
Results: The extent of the transitional area was significantly shorter with the nearest Alu elements
than with the nearest L1 and LTR elements, as well as in the extragenic regions containing a higher
density of retroelements than in the intragenic regions. The CpG islands neighbouring a high
density of Alu elements were consistently hypomethylated in both normal and tumor tissues. The
5'-transitional methylated CpG sites bordered by a low density of Alu elements or the L1 and LTR
elements were hypomethylated more frequently in the high-level LOH cases than in the low-level
LOH cases.
Conclusion:  The 5'-transitional methylated CpG sites not completely protected by the Alu
elements were hypomethylated in association with LOH events in gastric cancers. This suggests
that an irreversible unbalanced decrease in the genomic dose reduces the spread of L1 methylation
in the 5'-end regions of genes.
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Background
Unilateral chromosomal losses detected by a loss of heter-
ozygosity (LOH) analysis are the most common genetic
events in solid tumors [1]. The level of chromosomal
losses, rather than a single loss, has been consistently
shown to be a significant predictor of survival in stage II
and III gastrointestinal cancer patients [2-6]. Although
chromosomal losses are a part of gene inactivation, in a
naïve sense, the LOH events represent a reduction in the
dose of genetic elements. A dosage compensation mecha-
nism, which maintains the dose of the human genome,
equalizes the difference in the dose of the X chromosome
between males (XY) and females (XX) via pan-chromo-
somal epigenetic inactivation [7-9]. Therefore, it is impor-
tant to determine if the level of LOHs underlying the
clinical course of gastric cancer is associated with the epi-
genetic changes occurring in tumor cells as a result of an
unbalanced reduction of the genomic dose.
The distributions of the two major repetitive sequences in
the human genome, the Alu and L1 retroelements, are dif-
ferentially biased toward the CpG-rich euchromatic and
CpG-poor heterochromatic regions, respectively [10].
These self-replicating sequences are suppressed by hyper-
methylation because the vegetative copy generates inte-
grative copies resulting in the harmful influence of
insertion mutagenesis. In addition, the retroelements are
known to be potential centres for the spread of CpG meth-
ylation to the adjacent CpG sites [11-14]. The L1 elements
can boost the long-distance spread of heterochromatin
that is responsible for chromosome X inactivation [7,15].
Meanwhile, high-density Alu elements near the CpG-rich
islands are believed to spread CpG methylation over short
distances [16]. The short-distance spread of Alu methyla-
tion and the long-distance spread of L1 methylation
appear to construct the two distinct chromatin structures.
Repetitive sequences in eukaryotes can initiate and facili-
tate the spread of RNA-mediated chromatin condensation
through the pairing of homologous sequences [17]. Given
the interdependence of CpG methylation and chromatin
condensation, human retroelements can also cause the
spread of RNA-mediated methylation [15,18]. An analysis
of the relationship between the length of the CpG islands
and the position of the nearest retroelement revealed that
the spread of retroelement methylation can influence the
size of a CpG island [16]. Unilateral chromosomal losses
frequently occurring in tumor cells are accompanied by an
irreversible unbalanced decrease in the dose of genomic
and transcriptional retroelements. The colorectal cancer
genome suffering LOH events undergoes global
hypomethylation that affects the L1 retroelements [19]. In
addition, a study of gastric cancers reported a close rela-
tionship between the high-level LOHs and the hypometh-
ylation changes in the methylated CpGs near the CpG
islands [20]. Therefore, the LOH events might reduce the
spread of retroelement methylation as well as the methyl-
ation of the retroelement copies.
In this study of gastric cancers, the relationship between
the LOH events and the spread of retroelement methyla-
tion was examined by determining the correlation
between the extent of LOHs and the transitional CpG
methylation between the CpG islands and retroelements
in the 5'-end regions. The extent of the transitional area
was found to be shorter with the nearest Alu elements
than with the nearest L1 and LTR elements. The 5'-transi-
tional methylated CpG sites bordered by a low density of
Alu  elements or L1 and LTR elements were frequently
hypomethylated in the high-level LOH cases. This sug-
gests that unilateral chromosomal losses reduces the
spread of L1 methylation.
Methods
Computational analyses of the human genome
Information on the coding and non-coding sequences as
well as CpG islands was obtained from the human
genome database in the May, 2004 version [21]. A 1-kb
sized non-overlapping window was used to analyze the
sequence characteristics of a 10-kb segment upstream and
downstream from each transcription start site. This win-
dow analysis allowed an examination of the major regula-
tory regions, which are usually rich in protein binding
motifs, and at the same time, produced a profile of the 5'-
transitional CpGs between the CpG islands and their
nearest retroelements. The sequence data delimited from
the promoter regions were input into a local program to
calculate the coverage of CpG islands. A CpG island was
defined as a DNA segment with a G+C content ≥ 50%,
longer than 200 bp nucleotides, and an Observation/
Expectation CpG ratio > 0.6 [22]. A similar procedure was
used for the genomic position and annotation of retroele-
ments using the RepeatMasker program [23].
Patients and tumor tissues
The gastric cancer tissue and non-cancerous mucosa were
obtained from 50 patients who had undergone surgery
between March and December 2003 at St. Paul's Hospital,
The Catholic University of Korea. These fresh archives pro-
vided the genomic DNA that had been amplified effi-
ciently by methylation-specific PCR (MSP). The
histological classification of the gastric cancers was carried
out according to the Lauren's classification [24,25], and
the degree of differentiation was graded according to the
recommendations of the World Health Organization for
the histological typing of gastric cancer [26]. The Tumor-
Node-Metastasis (TNM) criteria were used to determine
the tumor stage based on the pathological and clinical
findings observed from radiography, ultrasonography,
computed tomography, and abdominal exploration dur-BMC Cancer 2006, 6:180 http://www.biomedcentral.com/1471-2407/6/180
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ing laparotomy. The Institutional Review Board approved
this study, and written informed consent was obtained
from each patient prior to the surgical resection.
A single 5–7 mm diameter tumor site containing a homo-
geneous cell content was selected from each representative
tissue section. Seven-µm-thick hematoxylin-eosin-stained
sections were microdissected under a 40-x stereomicro-
scope using a surgical scalpel. All the microdissected
tumor sites were checked for a tumor cell content ≥ 70%
prior to DNA extraction. A major fraction (33 sites, 66%)
of the microdissected tissues contained a tumor cell con-
tent of 80–89%, followed by ≥ 90% (12 sites, 24%) and
70–79% (5 sites, 10%). Approximately 50 microdissected
cells were digested in 1 µl of a Tween 20 – Proteinase K
lysis buffer. An average of 100 µl of each microdissected
tissue lysate was used for microsatellite analysis, and an
average of 500 µl of the same lysate was subjected to
bisulfite modification for methylation analysis.
PCR-based microsatellite analysis
The MSI (microsatellite instability) and LOH status of
each gastric cancer was determined using a panel of 40
microsatellite markers on eight cancer-associated chromo-
somes, 3p, 4p, 5q, 8p, 9p, 13q, 17p, and 18q, as reported
elsewhere (figure 1A) [5,6,27]. The MSI status of the mic-
rosatellite sequences was scored if there were any
frameshift mutations in > 40% of the homozygous mark-
ers. The unilateral reduction of the heterozygous allelic
bands was interpreted as LOH. The level of LOHs repre-
senting a significant reduction in the genomic dose was
determined based on the number of chromosomes show-
ing more than one LOH. According to the genetic classifi-
cation criterion of gastric cancers [6,27], the level of LOHs
was divided into low (LOH-L, less than four) and high
(LOH-H, four or more losses) levels for the intestinal-type
cancers, and baseline (LOH-B, zero or one loss), low
(LOH-L, two or three losses), and high (LOH-H, four or
more losses) levels for the diffuse-type cancers.
DNA modification by sodium bisulfite
Because the quality of the formalin-fixed tissue DNA var-
ied, the amount of template DNA was determined based
on a PCR band intensity of 20 ng/µl that had been ampli-
fied by the microsatellite primer set, D19S226 (forward,
5'-CCA GCA GAT TTT GGT GTT GTC TA-3'; reverse, 5'-
ACA GAG CCA GAG CCA GTA GGA GT-3'; amplicon size,
164 bp). Ninety microliters of the genomic DNA was
denatured with 10 µl of 3 M NaOH for 15 min at 37°C
before sodium bisulfite modification. This procedure
involved modifying 100 µl of the denatured DNA with
1,040 µl of 2.3 M sodium bisulfite and 60 µl of 10 mM
hydroquinone for 12 hr at 50°C, as described elsewhere
[20]. The modified DNA was then purified using a
genomic DNA purification kit (Promega, Madison, WI,
USA), precipitated with ethanol, and dissolved in 35 µl of
5 mM Tris buffer (pH 8.0). One µl aliquot of the modified
DNA solution was placed in the PCR tube and stored at -
20°C.
Semiquantitative methylation analysis
The semiquantitative methylation analysis using a radioi-
sotope was performed in a minimum of amplification
rounds for sub-plateau DNA amplification, as described
elsewhere [20]. A 1 µl aliquot of the bisulfite-modified
DNA was amplified and labeled in 10 µl of a hot-start PCR
solution containing an α-32P dTTP (PerkinElmer, Boston,
MA, USA) and dNTP mixture through 32 PCR cycles.
Thirty-two MSP primer sets were selected at the 5'-end
regions of 20 genes using the MethPrimer software [28]
(table 1). The sequences, PCR condition, and genomic
position of these primer set are listed in table 2 and [see
Additional file 1]. The coverage of CpG islands, the distri-
bution of retrolements, and the MSP primer position are
shown in the figure 2. Each MSP primer set was designed
to generate a small fragment of ≤ 150 bp, and yield a spe-
cific PCR intensity using the genomic DNA obtained from
the formalin-fixed paraffin-embedded tissues.
The specificity of each MSP primer set was validated using
a standard curve for the universal methylated and
unmethylated DNA (figure 1B). Based on the standard
curve of the control MSP bands, the density of the meth-
ylated CpGs was classified into 5 levels; level 1 (0–20%
methylation), level 2 (21–40% methylation), level 3 (41–
60% methylation), level 4 (61–80% methylation), and
level 5 (81–100% methylation). The intensity of the MSP
bands (figure 3A) was compared with the methylated
CpG content that was estimated by sequencing the com-
mon PCR DNA (figure 3B). The methylation levels esti-
mated by the MSP intensities were consistent with the
methylation densities measured from the common PCR
DNAs in 23 normal (96%) and 20 tumor (83%) DNAs of
24 normal and tumor DNA pairs (table 3).
In previous studies [29,30], the MSP bands visualized by
the ethidium bromide staining were classified into three
methylation levels (no, weak, and strong methylation).
Forty eight DNA specimens were amplified through 37
PCR cycles, of which six (13%) failed to generate any vis-
ible PCR bands by ethidium bromide staining (table 3).
Eight of the 42 visible MSP bands (19%) were scored dif-
ferently from the common PCR DNA. Twelve of the 14
DNA specimens (85%) showing no visible PCR bands or
inaccurate methylation levels were similarly scored by
both 32-cycle amplification using a radioisotope and
common PCR DNA. This high accuracy of the 32-cycle
amplification protocol allowed the MSP bands to be clas-
sified into five methylation levels.BMC Cancer 2006, 6:180 http://www.biomedcentral.com/1471-2407/6/180
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Representative autoradiographs of microsatellite analysis (A) and standard curves for methylation and unmethylation MSP  amplification (B) using a radioisotope Figure 1
Representative autoradiographs of microsatellite analysis (A) and standard curves for methylation and 
unmethylation MSP amplification (B) using a radioisotope. (A) A "multiplex, hot-start" method was applied to the 
PCR-based loss of heterozygosity (LOH) analysis. Forty microsatellite allelic loci were amplified in 25 reaction mixtures each of 
which contained one (10 mixtures) or two (15 mixtures) pairs of primers. A mixture of different-sized two to four amplicons 
was loaded onto one lane. A total of 80 microsatellite amplicons from each specimen were run simultaneously on one 
sequencing gel. Case 1 had high-level LOHs involving chromosome 4p, 5q, 9p, 13q, 17p, and 18q. The normal (N) and the cor-
responding tumor (T) DNAs are indicated above or below each microsatellite amplicon. The asterisk indicates a LOH. (B) The 
genomic DNA universally methylated by DNA methylase (CpGenome Universal Methylated DNA, Chemicon, Temecula, CA) 
was used as the methylated control DNA. The PCR DNA, which had been amplified by the universal primer (5'-CCG ACT 
CGA GNN NNN NAT GTG G-3'), was used as the unmethylated control DNA. Variable mixtures of the two opposite con-
trol DNAs according to their PCR intensity of 20 ng/µl were amplified using a set of MSP primers for the non-island CpGs of 
the TFF2 gene. The proportion of methylated and unmethylated CpGs was calculated using the following formula: Methylation 
or unmethylation proportion (%) = (methylation or unmethylation intensity/(methylation + unmethylation intensity)) × 100. 
The relative band intensities of the methylation (M, closed circle) and unmethylation (U, open circle) primer set were plotted 
as a function of the control DNA content. The amplification intensity ratio of the MSP primer set increased linearly with 
increasing percentage of the corresponding control DNA in the MSP mixtures.BMC Cancer 2006, 6:180 http://www.biomedcentral.com/1471-2407/6/180
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When 80 normal and tumor DNA pairs showing a one-
level methylation difference were analyzed, 71 pairs
(89%) demonstrated same-level methylation differences
in the MSP band intensities and the common PCR DNA
[see Additional file 2].
Statistical analysis
The Pearson's correlation coefficient was used to deter-
mine the correlation between (i) the MSP band intensity
and the proportion of methylated and unmethylated con-
trol DNA, (ii) the coverage of CpG islands and the density
of retroelements, and (iii) the frequency of methylation
alterations and the level of LOHs using SPSS ver. 11.0 soft-
ware. A χ2 test or Fisher's exact test and an independent t
test were used to compare the clinicopathological varia-
bles or the frequency of methylation alterations between
the different microsatellite genotypes. Two-sided p values
< 0.05 were considered significant.
Results
Analysis of the transitional area between the CpG Islands 
and the nearest retroelements
Of a total of 22,297 genes examined, 10,515 and 11,782
were found to have a single CpG island and no CpG
islands at the transcription start site, respectively. The den-
sities of Alus, L1s, and LTRs in a 1-kb window were plotted
separately a distance 10 kb upstream and downstream
from the transcription start sites. Figure 4A revealed the
following: (i) the densities of the three retroelement types
were commonly higher in the extragenic 10-kb regions
than in the 10-kb intragenic regions. (ii) the three retroe-
lement types were commonly depressed in both the intra-
genic and extragenic first 1-kb regions, (iii) the density of
depressed retroelements was lower in the first 1-kb
regions containing CpG islands than in the regions con-
taining no CpG islands, (iv) the density of Alu copies rap-
idly reached a plateau at a distance of 3 kb, which was
higher in the 5'-end regions containing CpG islands than
in the regions containing no CpG islands.
A transitional area between the CpG islands and their
nearest retroelements was demarcated by a distance from
the 5'(3')-end of the CpG island to the position of the
nearest retroelement in the extragenic (intragenic) region
(figure 4B). Figure 4C shows that the CpG islands fre-
quently neighbored the nearest Alu elements (76% and
83%) and infrequently the nearest L1 (13% and 11%) and
LTR (11% and 6%) elements in both the extragenic and
intragenic regions. Figure 4D shows that the mean extent
of the transitional area between the CpG island and the
nearest retroelement was significantly shorter in the extra-
genic regions (989 bp) than in the intragenic regions
(1,700 bp). The mean extent of the extragenic and intra-
genic transitional area bordered by the nearest Alu ele-
Table 1: Summary of 20 genes examined by methylation analysis
Gene symbol Synonym Gene description Accession no.
CpG islands
CDH1 E-CADHERIN Cadherin 1, type 1, E-cadherin (epithelial) NM_004360
RABGEF1 AJ250042 RAB guanine nucleotide exchange factor (GEF) 1 NM_014504
STAG1 SA1 Stromal antigen 1 NM_005862
MYBPC2 AJ250042 Myosin binding protein C, fast type NM_004533
VDR J03258 Vitamin D (1,25- dihydroxyvitamin D3) receptor NM_000376
ESR2 AF051428 Estrogen receptor 2 (ER beta) NM_001437
MLH1 HMLH1 MutL homolog 1, colon cancer, nonpolyposis type 2 NM_000249
FLJ43855 AK125843 similar to sodium- and chloride-dependent creatine transporter NM_198857
PTEN BZS Phosphatase and tensin homolog NM_000314
CDKN2A P16 Cyclin-dependent kinase inhibitor 2A NM_000077
PAX5 AY463952 Paired box gene 5 (B-cell lineage specific activator) NM_016734
RUNX2 CBFA1 Runt-related transcription factor 2 NM_004348
RUNX3 CBFA3 Runt-related transcription factor 3 NM_004350
KIAA1752 Homo sapiens mRNA for KIAA1752 protein AB051539*
MUC8 Mucin 8, tracheobronchial U14383*
Non-island CpGs
MAGEA2 MAGE-A2 Melanoma antigen family A, 2 NM_005361
DDX53 CAGE DEAD (Asp-Glu-Ala-Asp) box polypeptide 53 NM_182699
TFF2 SML1 Trefoil factor 2 (spasmolytic protein 1) NM_005423
SERPINB5 MASPIN Serpin peptidase inhibitor, clade B (ovalbumin), member 5 NM_002639
MSLN MPF Mesothelin isoform 2 precursor NM_013404
*GenBank accession number.BMC Cancer 2006, 6:180 http://www.biomedcentral.com/1471-2407/6/180
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ments (945 bp and 1,645 bp) was significantly shorter
than that by the nearest L1 (1,063 bp and 1,853 bp) and
LTR (1,104 bp and 1,967 bp) elements.
Genetic classification of gastric cancers according to the 
level of LOHs
The allelic profiles of the 40 microsatellite sequences were
initially analyzed for a MSI at the homozygous markers
that showed a few shadow or stutter bands in a pair of
normal and tumor DNAs. Five of 50 gastric cancers exam-
ined had a high-frequency MSI in more than 40% of the
homozygous alleles examined. A LOH was analyzed at the
stable heterozygous alleles in the remaining 45 MSI-nega-
tive gastric cancers. The number of chromosomes showing
more than one LOH event was counted in each MSI-neg-
ative case. Using the number of chromosomal losses, the
extents of LOH was categorized into high level involving
four or more chromosomes (LOH-H) and low level
involving less than four chromosomes (LOH-L) for intes-
tinal-type cancers. One and zero chromosomal loss were
scored as baseline-level loss (LOH-B) for diffuse-type can-
cers. Overall, 20 LOH-H (40%), 19 LOH-L (38%), 6 LOH-
B (12%), and 5 MSI (10%) cases were identified in the 50
surgical specimens (table 4). A comparison of the clinico-
pathological variables in the LOH-H and LOH-L gastric
cancers revealed a lymphatic invasion (p = 0.001) and
advanced stage (p = 0.015) to be significantly associated
with the LOH-H cases. Intestinal-type cancers (p = 0.032)
as well as well and moderate differentiation (p = 0.046)
were more frequent in the LOH-L cases.
Table 2: CpG dinucleotides examined by methylation-specific polymerase chain reaction
Primer position* Intensity ratio†
Gene Chromosome locus CpG sites (kb)* CpG ratio GC% U M U U/M‡ M
CDH1 16q22 0 0.73 70 -78 -76 0.92 0.49/0.51 0.94
RABGEF1 7q11 -0.2 1.00 67 -285 -283 0.9 0.46/0.54 0.91
STAG1 3q22 -0.4 0.95 62 -493 -490 0.93 0.51/0.49 0.91
MYBPC2 19q13 -1.2 0.61 61 -1,226 -1,224 0.92 0.48/0.52 0.94
-0.6 0.83 67 -742 -742 0.9 0.51/0.49 0.88
VDR 12q13 -0.7 0.71 58 -728 -727 0.92 0.51/0.49 0.92
+0.1 0.84 63 +45 +45 0.95 0.51/0.49 0.94
ESR2 14q23 -0.9 0.66 59 -983 -986 0.85 0.48/0.52 0.91
MLH1 3p22 -1.0 0.43 49 -1,098 -1,098 0.93 0.51/0.49 0.95
-0.6 0.85 63 -660 -655 0.94 0.48/0.52 0.93
FLJ43855 16p11 -1.1 0.62 55 -1147 -1147 0.89 0.48/0.52 0.90
PTEN 10q23 -1.4 0.66 62 -1,425 -1,425 0.93 0.52/0.48 0.91
-0.9 0.86 62 -953 -953 0.94 0.51/0.49 0.93
CDKN2A 9p21 -1.5 0.77 65 -1,580 -1,575 0.9 0.47/0.53 0.93
0 1.10 65 -85 -85 0.91 0.47/0.53 0.91
+0.8 0.48 51 776 775 0.93 0.51/0.49 0.96
PAX5 9p13 -1.0 0.50 63 -1,056 -1,054 0.92 0.52/0.48 0.90
RUNX2 6p21 -3.8 0.25 36 -3,883 -3,883 0.9 0.48/0.52 0.93
-3.0 0.71 55 -3,061 -3,061 0.91 0.49/0.51 0.92
-0.7 0.81 62 -852 -850 0.93 0.52/0.48 0.92
+1.6 0.63 53 1573 1573 0.92 0.47/0.53 0.94
RUNX3 1p36 -1.7 0.82 60 -1,790 -1,790 0.89 0.46/0.54 0.9
-0.5 0.94 75 -559 -559 0.91 0.48/0.52 0.9
-0.1 1.07 76 -219 -217 0.92 0.5/0.5 0.93
+1.0 0.79 59 952 952 0.91 0.49/0.51 0.93
KIAA1752 16q12 +0.4 0.42 41 391 391 0.92 0.48/0.52 0.94
MUC8 12q24 +2.0 0.42 59 1,909 1,909 0.94 0.49/0.51 0.95
MAGEA2 Xq28 0 0.56 64 -81 -75 0.9 0.54/0.46 0.91
DDX53 Xq22.11 0 0.53 59 -71 -102 0.94 0.48/0.52 0.94
TFF2 21q22 -0.2 0.32 57 -251 -251 0.96 0.5/0.5 0.96
SERPINB5 18q21 -0.3 0.62 51 -315 -308 0.93 0.51/0.49 0.94
MSLN 16q13 -0.8 0.52 57 -827 -827 0.92 0.47/0.53 0.93
*The genomic position was calculated from the May 2004 human reference sequence.
†The relative proportion of unmethylation (U) and methylation (M) band intensity against the total band intensity.
‡U/M indicates a PCR mixture containing the same amount of the universal methylated and unmethylated DNA.BMC Cancer 2006, 6:180 http://www.biomedcentral.com/1471-2407/6/180
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Schematic diagram of CpG islands and retroelement distributions in the 5'-end regions of 20 genes Figure 2
Schematic diagram of CpG islands and retroelement distributions in the 5'-end regions of 20 genes. A total of 32 
CpG amplicon sites from 20 genes were examined using the methylation-specific PCR (MSP) primer sets. The CpG islands of 
the CDH1, RABGEF1, STAG1, and MYBPC2 genes were neighbored by the high-density Alu elements at distances of ≤ 1 kb. The 
VDR, ESR2, MLH1, FLJ43855, MYBPC2, PTEN, and CDKN2A genes confronted by a low density of Alu, L1, and LTR elements at a 
distance of 2–6 kb were examined at the boundary of CpG islands. The PAX5, RUNX2, and RUNX3 genes contained long CpG 
islands bordered by a few retroelements at distances of > 6 kb. The genes containing no CpG islands are confronted by the L1 
elements (MAGEA2 and TFF2), a low density of Alu elements (SERPINB5 and DDX53), or a high density of Alu and L1 elements 
(MSLN). The VDR, CDKN2A, RUNX2, RUNX3, KIAA1752, and MUC8 genes were examined at the intragenic CpG sites of the 
CpG islands as well. The MSP primer sites were located in close proximity to the transcription start sites without CpG islands.BMC Cancer 2006, 6:180 http://www.biomedcentral.com/1471-2407/6/180
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Representative autoradiographs of semiquantitative methylation analysis (A) and the number and position of the methylated  CpGs identified by the sequencing of common PCR DNA (B) Figure 3
Representative autoradiographs of semiquantitative methylation analysis (A) and the number and position of 
the methylated CpGs identified by the sequencing of common PCR DNA (B). (A) The 5'-transitional CpG sites gen-
erated a wide range of methylated and unmethylated PCR band intensities from the bisulfite-modified DNA from Case 1, with 
a high-level chromosomal loss, and Case 26, with a low-level chromosomal loss. The lanes marked U and M indicate the PCR 
bands of the unmethylation and methylation primer sets, respectively. The level of the methylated CpGs calculated from a 
standard MSP curve is indicated below the lanes. (B) For the same cases, the content of methylated CpGs was estimated from 
the common PCR DNA containing both the methylated and unmethylated CpGs. Ten common PCR clones per DNA sample 
were sequenced. The content of methylated CpGs is indicated as a percentage on the left side of each CpG methylation map. 
The different methylation results between the MSP bands and the common PCR DNAs are indicated by an asterisk.BMC Cancer 2006, 6:180 http://www.biomedcentral.com/1471-2407/6/180
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Table 3: The density of methylation estimated by semiquantitative methylation-specific PCR analysis and sequencing of common PCR 
DNA
Methylation-specific PCR
CpG sites* Case no. 32-cycle amplicons using 
radioisope
37-cycle amplicons using 
ethidium bromide
% Methylation in 10 common 
PCR clones
MYBPC2, -1.2 kb 1 Normal Level 4 Level 4 53/70‡ (76%)
Tumor Level 4 Level 4 48/70 (69%)
26 Normal Level 4 Level 4 47/70 (67%)
Tumor Level 3 No band 32/70 (46%)
VDR, -0.7 kb 1 Normal Level 1 Level 1 4/130 (3%)
Tumor Level 1 Level 1 12/130 (9%)
26 Normal Level 2 Level 2 44/130 (34%)
Tumor Level 3 Level 3 64/130 (49%)
MLH1, -1.0 kb 1 Normal Level 3 Level 3 14/30 (47%)
Tumor Level 2 Level 3† 10/30 (33%)
26 Normal Level 2 No band 9/30 (30%)
Tumor Level 4† Level 3 17/30 (57%)
MLH1, -0.6 kb 1 Normal Level 1 Level 1 0/200 (0%)
Tumor Level 1 Level 1 0/200 (0%)
26 Normal Level 1 Level 1 4/200 (2%)
Tumor Level 1 Level 1 4/200 (2%)
CDKN2A, -1.5 kb 1 Normal Level 2 Level 2 19/60 (32%)
Tumor Level 1 Level 1 5/60 (8%)
26 Normal Level 2 Level 2 13/60 (22%)
Tumor Level 5 No band 54/60 (90%)
CDKN2A, 0 kb 1 Normal Level 1 Level 1 0/110 (0%)
Tumor Level 1 Level 1 0/110 (0%)
26 Normal Level 1 Level 1 0/110 (0%)
Tumor Level 4 Level 3† 76/110 (69%)
RUNX2, -3.0 kb 1 Normal Level 1 Level 1 8/60 (13%)
Tumor Level 1 Level 1 8/60 (13%)
26 Normal Level 2† No band 11/60 (18%)
Tumor Level 2† Level 1 9/60 (15%)
RUNX3, -1.7 kb 1 Normal Level 1 Level 1 6/70 (10%)
Tumor Level 3 Level 3 38/70 (54%)
26 Normal Level 2 Level 3† 27/70 (39%)
Tumor Level 4 Level 3† 45/70 (64%)
MAGEA2, 0 kb 1 Normal Level 5 Level 5 106/110 (96%)
Tumor Level 2 Level 2 41/110 (37%)
26 Normal Level 5 Level 5 104/110 (95%)
Tumor Level 5 Level 5 103/110 (94%)
TFF2, -0.2 kb 1 Normal Level 2 Level 3† 21/60 (35%)
Tumor Level 2 Level 3† 19/60 (32%)
26 Normal Level 3 Level 3 32/60 (53%)
Tumor Level 2† Level 3 25/60 (42%)
SERPINB5, -0.3 kb 1 Normal Level 3 Level 3 36/70 (51%)
Tumor Level 2† No band 31/70 (44%)
26 Normal Level 2 Level 3† 26/70 (37%)
Tumor Level 2 No band 27/70 (39%)
MSLN, -0.8 kb 1 Normal Level 5 Level 5 66/70 (94%)
Tumor Level 3 Level 4† 38/70 (54%)
26 Normal Level 4 Level 4 51/70 (73%)
Tumor Level 5 Level 5 61/70 (87%)
*CpG sites are indicated by the name of the gene and the distance from the transcription start site.
†Different results between methylation-specific PCR and common PCR DNA.
‡'/' separates the number of the methylated CpGs and the total CpGs.BMC Cancer 2006, 6:180 http://www.biomedcentral.com/1471-2407/6/180
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Relationships between the LOHs and methylation 
alterations
Fifty pairs of normal and tumor tissues were examined
using the MSP primer sets for a total of 32 CpG amplicon
sites (figure 5). The CpG islands of the CDH1, RABGEF1,
and STAG1 genes, which neighbored a high density of Alu
elements at a distance < 2 kb, were found to be hypometh-
ylated in the normal tissues at a level < 2. These CpG
islands showed few methylation alterations in the tumor
tissues. The transitional CpGs of the MYBPC2 gene bor-
dered by the high-density Alus were hypermethylated at a
level ≥ 3 in the normal tissues but were unchanged in the
tumor tissues. The long CpG islands of the PAX5  and
RUNX2 genes neighboring a small number of retroele-
ments at a long distance, > 6 kb, showed insignificant
methylation alterations in the tumor tissues.
The CpG island boundaries neighboring a low density of
Alu elements or L1 and LTR elements at a distance of 2–6
kb became increasingly methylated at a level of ≥ 2. The
CpG sites in close proximity to the transcription start sites
with no accompanying CpG islands were densely methyl-
ated at a level of ≥ 3. The CpG island boundaries and the
proximal sites of the non-CpG-island genes were catego-
rized as transitional CpGs, because these CpG sites could
be distinguished from the proximal sites of the CpG
islands that are consistently unmethylated. The methyla-
tion level of these 5'-transitional CpGs in the normal and
Distributions of the Alu, L1, and LTR retroelements in the 5'-end regions of the human genes Figure 4
Distributions of the Alu, L1, and LTR retroelements in the 5'-end regions of the human genes. (A) The proportion 
of Alu, L1, and LTR elements in a 1-kb nucleotide bin were plotted separately in both extragenic and intragenic 10-kb segments. 
(B) The transitional area is demarcated by the distance between the 5'(3')-end of a CpG island and the extragenic (intragenic) 
nearest retroelements. The number of genes (C) and the mean extent of the transitional area (D) were calculated according 
the position and type of the nearest retroelements.BMC Cancer 2006, 6:180 http://www.biomedcentral.com/1471-2407/6/180
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tumor DNA was compared (table 5). The methylation
level of the LOH-H cancers was significantly lower at the
5'-transitional CpG sites of the VDR, FLJ43855, CDKN2A,
MUC8, MAGEA2, and MSLN genes. The LOH-L cancers
had a significantly higher methylation level at the 5'-tran-
sitional CpG sites of the MLH1 and CDKN2A genes.
The frequency of methylation alterations occurring in a
total of 14 transitional CpG amplicons was scored accord-
ing to the number of the amplicons showing a difference
in the level of methylation between the normal and tumor
DNA. The frequency of hypomethylation and hypermeth-
ylation in the transitional CpGs were linearly (r = 0.738, p
< 0.0001) and inversely (r = 0.673, p < 0.0001) propor-
tional to the number of chromosomal losses, respectively,
(figure 6A and 6B). There were significant differences in
the mean frequency of hypomethylation (44% versus
15%) and hypermethylation (5% versus 26%) between
the LOH-H and LOH-L cancers (p < 0.0001) (figure 6C
and 6D). The frequency of hypermethylation in the tran-
sitional CpGs was highest in the MSI cases.
Although the proximal portion of the CpG islands was
largely unmethylated in both the normal and tumor
DNAs, the CpG islands of the MLH1 and RUNX3 genes
was hypermethylated in most tumor tissues with a MSI
(MLH1) and LOH-B (RUNX3), respectively (figure 5). The
distal portion of the RUNX3 CpG island was frequently
hypermethylated in both LOH-H and LOH-L cases.
Relationships between methylation alterations and the 
clinicopathological features
The relationship between the frequency of methylation
alterations and the clinicopathological features was ana-
lyzed in 39 gastric cancers with high-level and low-level
chromosomal losses (table 6). The frequency of
hypomethylation in the transitional area increased with
increasing lymphatic invasion (p = 0.006) and advanced
Table 4: Clinicopathological characteristics of gastric cancers according to the level of loss of heterozygosity (LOH) and microsatellite 
instability*
Total High LOH Low LOH p† Baseline LOH Microsatellite instability
No. of patients 50 20 19 6 5
Age (years)
Mean ± SD 59.6 ± 12.6 60.5 ± 11.7 61.1 ± 11.6 0.883 55.0 ± 7.9 66.8 ± 7.3
Tumor size (cm)
Mean ± SD 4.9 ± 2.8 5.2 ± 2.7 4.4 ± 3.1 0.402 4.3 ± 1.8 6.3 ± 3.2
Sex
Male 32 15 12 0.325 3 2
Female 18 5 7 3 3
Lauren classification
Intestinal 29 10 16 0.032 0 3
Diffuse 11 5 3 3 0
Mixed 10 5 0 3 2
Differentiation
W e l l 403 0 . 0 4 6 0 1
Moderate 26 11 13 0 2
Poor 20 9 3 6 2
Growth pattern
Infiltrative 27 14 9 0.126 2 2
Expanding 3 0 3 0 0
Mixed 20 6 7 4 3
Venous invasion
Y e s 640 0 . 0 5 9 2 0
No 44 16 19 4 5
Lymphatic invasion
Yes 29 16 5 0.001 5 3
N o 2 141 4 1 2
Tumor stage
Early stage 29 8 15 0.015 2 4
Advanced stage 21 12 4 4 1
*The classification of microsatellite genotypes is detailed in the "Material and Method" section.
†p values were calculated between the low LOH and high LOH cases by an independent t test for the age and tumor size variables and by a Fisher's 
exact test or a χ2 test for other variables.BMC Cancer 2006, 6:180 http://www.biomedcentral.com/1471-2407/6/180
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Methylation profiles of the CpG islands and the 5'-transitional CpGs examined in the normal (N) and tumor (T) tissues of gas- tric cancer patients using semiquantitative methylation-specific PCR analysis Figure 5
Methylation profiles of the CpG islands and the 5'-transitional CpGs examined in the normal (N) and tumor 
(T) tissues of gastric cancer patients using semiquantitative methylation-specific PCR analysis. The methylation 
status was classified into 5 levels. Gastric cancers were classified into four microsatellite genotypes. The level of methylation 
and the classification of the microsatellite genotypes are detailed in the "Materials and Methods" section. All the information 
regarding the methylation analysis is listed in table 1 and 2. CpG sites are indicated by the name of the gene and the distance 
from the transcription start site.BMC Cancer 2006, 6:180 http://www.biomedcentral.com/1471-2407/6/180
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tumor stage (p = 0.015). The frequency of hypermethyla-
tion decreased with increasing venous invasion (p =
0.041), lymphatic invasion (p = 0.003), and advanced
tumor stage (p = 0.023).
Of a total of 598 methylation alterations, 472 (79%)
showed a one-level difference in methylation between the
paired normal and tumor DNA and 126 (21%) showed a
two- or higher-level difference with an inverse methyla-
tion status between the normal and tumor DNA [see
Additional file 2]. The normal tissues of the LOH-H and
LOH-L cases showed a similar level of methylation in the
transitional area.
Discussion
It was previously reported that the short-distance spread
of Alu methylation acts as a barrier blocking the long-dis-
tance spread of L1 methylation [16]. In this study, the
transitional area bordered by Alu  elements was signifi-
cantly shorter than that bordered by the L1 elements,
which concurs with a previous report [16]. CpG islands
neighboring the high-density Alu elements were invaria-
bly hypomethylated in both the normal and tumor tis-
sues. The long CpG islands of the PAX5 and RUNX2 genes
that neighbored a few retroelements showed insignificant
methylation alterations. The 5'-transitional methylated
CpGs bordered by either low-density Alu  elements or
Table 5: Methylation alterations in the CpG islands and the 5'-transitional CpG sites examined in gastric cancers containing high-level 
and low-level chromosomal losses
High-level chromosomal loss (n = 20) Low-level chromosomal loss (n = 19)
Mean level of methylation Methylation alterations (%) Mean level of methylation Methylation alterations (%)
CpG sites* Normal Tumor p† Hypo- Hyper- Normal Tumor p† Hypo- Hyper-
CpG islands
CDH1, 0 kb 1.2 1.0 0.083 3 (15) 0 (0) 1.1 1.1 0.560 0 (0) 1 (5)
RABGEF1, -0.2 kb 1.1 1.0 0.163 2 (10) 0 (0) 1.0 1.0 1 0 (0) 0 (0)
STAG1, -0.4 kb 1.1 1.0 0.330 1 (5) 0 (0) 1.0 1.0 1 0 (0) 0 (0)
MYBPC2, -0.6 kb 1.6 1.6 0.757 2 (10) 1 (5) 2.0 2.3 0.090 0 (0) 4 (21)
MLH1, -0.6 kb 1.4 1.4 1 5 (25) 2 (10) 1.3 1.7 0.153 0 (0) 4 (21)
PTEN, -0.9 kb 1.3 1.2 0.442 2 (10) 0 (0) 1.1 1.1 0.560 1 (5) 2 (11)
CDKN2A, 0kb 1.1 1.0 0.330 1 (5) 0 (0) 1.0 1.4 0.072 0 (0) 4 (21)
PAX5, -1.0 kb 2.0 1.7 0.115 7 (35) 0 (0) 1.9 2.1 0.505 4 (21) 5 (26)
RUNX2, -3.8 kb 4.2 3.8 0.054 7 (35) 0 (0) 4.2 4.3 0.376 1 (5) 4 (21)
-3.0 kb 1.8 1.8 1 5 (25) 5 (25) 2.0 2.0 1 3 (16) 4 (21)
-0.7 kb 2.1 2.0 0.575 5 (25) 4 (20) 1.7 1.9 0.266 4 (21) 6 (32)
+1.6 kb 2.0 2.2 0.295 3 (15) 5 (25) 2.1 2.5 0.066 2 (11) 7 (37)
RUNX3, -1.7 kb 2.0 3.3 <0.0001 0 (0) 14 (70) 2.5 3.3 0.012 0 (0) 12 (63)
-0.5 kb 1.3 1.1 0.121 6 (30) 2 (10) 1.8 2.4 0.035 2 (11) 9 (47)
-0.1 kb 1.2 1.0 0.042 4 (20) 0 (0) 1.0 1.2 0.042 0 (0) 4 (21)
+1.0 kb 4.0 3.8 0.519 6 (30) 5 (25) 3.4 3.8 0.012 0 (0) 7 (37)
VDR, +0.1 kb 1.0 1.0 1 0 (0) 0 (0) 1.0 1.0 1 0 (0) 0 (0)
KIAA1752, +0.4 kb 2.8 2.6 0.096 8 (40) 0 (0) 2.1 2.5 0.084 0 (0) 7 (37)
Transitional CpGs
MYBPC2, -1.2 kb 4.3 4.1 0.083 4 (20) 0 (0) 4.3 4.2 0.546 5 (26) 2 (11)
VDR, -0.7 kb 1.8 1.3 0.003 10 (50) 0 (0) 1.5 2.1 0.056 3 (16) 8 (42)
ESR2, -0.9 kb 1.7 1.4 0.114 6 (30) 0 (0) 1.3 1.5 0.141 0 (0) 4 (22)
MLH1, -1.0 kb 3.1 2.5 0.050 9 (45) 2 (10) 2.8 3.5 0.035 1 (5) 11 (58)
FLJ43855, -1.1 kb 4.0 3.5 0.043 10 (50) 2 (10) 3.7 4.1 0.072 2 (11) 8 (42)
PTEN, -1.4 kb 1.4 1.1 0.062 5 (25) 0 (0) 1.1 1.3 0.119 1 (5) 5 (26)
CDKN2A, -1.5 kb 2.0 1.6 0.012 10 (50) 2 (10) 2.0 2.8 0.025 3 (16) 10 (53)
+0.8 kb 4.4 3.6 0.002 12 (60) 0 (0) 4.1 4.4 0.173 3 (16) 7 (37)
MUC8, +2.0 kb 4.4 3.7 0.001 9 (45) 0 (0) 4.4 4.2 0.149 6 (32) 2 (11)
MAGEA2, 0 kb 4.8 3.4 <0.0001 11 (55) 0 (0) 4.8 4.6 0.336 2 (11) 0 (0)
DDX53, 0 kb 4.2 3.7 0.051 9 (45) 2 (10) 4.5 3.9 0.096 6 (32) 2 (11)
TFF2, -0.2 kb 2.4 2.1 0.174 7 (35) 2 (10) 2.2 2.0 0.324 6 (32) 2 (11)
SERPINB5, -0.3 kb 2.7 2.2 0.080 10 (50) 3 (15) 2.4 2.5 0.598 2 (11) 4 (21)
MSLN, -0.8 kb 4.3 3.6 0.005 11 (55) 2 (10) 3.5 3.7 0.591 1 (5) 5 (26)
*CpG sites are indicated by the name of the gene and the distance from the transcription start site.
†p values were calculated by an independent t test for the mean values.BMC Cancer 2006, 6:180 http://www.biomedcentral.com/1471-2407/6/180
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Relationships between methylation alterations and the number of chromosomal losses in gastric cancers Figure 6
Relationships between methylation alterations and the number of chromosomal losses in gastric cancers. The 
frequency of hypomethylation (A) and hypermethylation (B) detected in 14 transitional CpG amplicons was plotted as a func-
tion of the chromosomal losses. The correlation coefficients were calculated using Pearson's correlation analysis. The correla-
tion between methylation alterations and chromosomal losses is shown with the line of best fit. The mean frequency of 
hypomethylation (C) and hypermethylation (D) was compared among four microsatellite genotypes.BMC Cancer 2006, 6:180 http://www.biomedcentral.com/1471-2407/6/180
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other retroelements were frequently hypomethylated in
the LOH-H cases (table 5). This suggests that LOH events
have no influence on the unmethylated CpG islands that
are protected by high-density Alu elements. In contrast,
the transitional methylated CpG sites under long-distance
L1 methylation which are either not protected or only par-
tially protected by the Alu elements, were hypomethylated
in association with the LOHs.
In a Drosophila model, repetitive RNA is believed to diffuse
through the nucleus and assemble onto other homolo-
gous copies to initiate the spread of the heterochromatin
signal [31]. This study found that the intragenic regions
contained low-density retroelements compared with the
extragenic regions, whereas the transitional area was
longer in the intragenic regions than in the extragenic
regions (figure 4D). The intragenic retroelements releas-
ing RNA, expressed in initial embryogenesis, are believed
to have a higher probability for encountering homolo-
gous RNA sequences to promote the further spread of
methylation compared with extragenic copies releasing
fewer RNA. Therefore, the 5'-transitional CpG sites
affected by the RNA-mediated spread of L1 methylation
are likely to be hypomethylated as a result of chromo-
somal losses.
The hypomethylation of imprinted genes is often
observed in gastric cancers but not associated with a LOH
involving the counterpart chromosome [32,33]. The
losses of chromosome 9p (CDKN2A) and 3p (MLH1)
examined in a previous study [20] were not associated
with the hypomethylation of the transitional CpGs of the
CDKN2A and MLH1 genes. This suggests that epigenetic
alterations in response to the LOH events are more likely
to result from genome-wide compensation than chromo-
some by chromosome compensation. Meanwhile, a previ-
ous study on colonic cancers reported that the LOH events
examined on three chromosomes were associated with
Table 6: Relationships between methylation alterations and clinicopathological variables in gastric cancers (n = 39) containing high-
level and low-level chromosomal losses
Mean frequency of methylation alterations* (%, mean ± SD)
Clinicopathological variables No. of patients Hypomethylation p† Hypermethylation p†
Age (years)
≤55 7 34.7 ± 28.4 0.547 11.2 ± 9.1 0.384
>55 32 29.0 ± 20.1 16.5 ± 15.2
Tumor size (cm)
≤5 24 24.7 ± 16.7 0.056 17.3 ± 15.6 0.359
> 5 15 38.6 ± 27.4 12.9 ± 12.1
Sex
Male 27 28.8 ± 22.2 0.619 14.5 ± 15.0 0.514
Female 12 32.7 ± 22.9 17.8 ± 13.1
Lauren classification
Intestinal 26 28.0 ± 21.3 0.727 18.1 ± 15.0 0.189
Diffuse 8 34.8 ± 29.4 13.4 ± 12.9
Mixed 5 32.9 ± 15.6 5.7 ± 9.3
Differentiation
Well 3 23.8 ± 10.9 0.671 23.8 ± 8.2 0.169
Moderate 24 28.6 ± 22.2 17.6 ± 15.3
Poor 12 34.5 ± 24.7 9.5 ± 11.9
Growth pattern
Infiltrative 23 32.6 ± 25.6 0.639 13.4 ± 12.9 0.221
Expanding 3 21.4 ± 14.3 28.6 ± 14.3
Mixed 13 27.4 ± 16.7 16.5 ± 16.1
Venous invasion
Yes 4 37.5 ± 16.9 0.485 1.8 ± 3.6 0.041
No 35 29.2 ± 22.7 17.1 ± 14.3
Lymphatic invasion
Yes 21 38.8 ± 25.2 0.006 9.5 ± 10.4 0.003
No 18 19.8 ± 12.1 22.6 ± 15.3
Tumor stage
Early stage 23 23.0 ± 15.1 0.015 19.9 ± 15.7 0.023
Advanced stage 16 40.2 ± 26.9 9.4 ± 9.7
*Methylation alterations were detected in 14 transitional CpG amplicons.
†p values were calculated by an independent t test.BMC Cancer 2006, 6:180 http://www.biomedcentral.com/1471-2407/6/180
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global L1 hypomethylation [19]. In this study on gastric
cancers, there is a significant difference in L1-associated
methylation between the LOH-H and LOH-L cases. There-
fore, the reduced spread of methylation in the transitional
area is likely due to LOH events accompanying an unbal-
anced decrease in the genomic L1 dose.
Previous multifocal LOH studies [6,27,34,35] reported
that heterogeneous tumor sites shared a similar level of
LOHs involving the same and different chromosomes.
Interestingly, heterogeneous tumor sites of multidirec-
tionally differentiated cancers such as a glandular-neu-
roendocrine carcinoma [34], sarcomatoid carcinoma
[35], and gastric cancers [6,20,27] frequently demon-
strated reciprocal losses involving the opposite alleles on
the same chromosome. This suggests that a similar level of
LOHs rather than the genomic position drives the sub-
clonal expansion of heterogeneous tumor cells with a sim-
ilar growth advantage, and that the level of LOHs acts as a
stem-line genotype driving tumor progression.
A previous report on multifocal methylation analysis [20]
showed that the methylation alterations associated with
the level of LOHs were scored differentially in heterogene-
ous sites from a given gastric cancer. This suggests that
chromosomal losses cause sideline methylation altera-
tions and initiate intratumoral methylation heterogene-
ity. The transitional CpG sites of individual genes mostly
demonstrated a one-level difference in the methylation
status between normal and tumor tissues [see Additional
file 2]. Bisulfite sequencing analyses using the tumor cell
lines and pure primary tissues revealed low-density meth-
ylation in the unmethylated CpG islands [36-39]. How-
ever, the high tumor cell content examined in this study
unambiguously demonstrated LOH events. Therefore,
low-level methylation changes are the result of methyla-
tion heterogeneity rather than the low tumor cell content.
The hypomethylation of the 5'-transitional CpG sites was
associated with the clinicopathological variables in terms
of the similarities to the LOH-H cases (tables 4 and 6). The
LOH-H cases have been reported to be associated with a
poor prognosis [4,6,27]. The poor clinical course of gastric
cancer might be the result of an interaction between stem-
line high-level LOHs and sideline hypomethylation. Con-
sidering that the 5'-transitional CpG sites were methylated
to various degrees in a tissue-specific manner [16], the
hypomethylation of the transitional CpGs may play a role
in the malignant cellular transformation. Extra-embryonic
trophoectodermal cells highlight the invasive potential of
hypomethylated cells, which penetrate the endometrium
during early embryogenesis and implantation. A number
of studies have reported hypomethylated trophoblast cells
to be well equipped with the biochemical mediators
essential for invasive growth and metastasis in a similar
manner to transformed tumor cells [40]. Therefore, it
appears that the transformation, invasion, and metastasis
of tumor cells is dynamically stimulated by the stochastic
hypomethylation in response to LOH events rather than
by the simple up-regulation of gene expression.
The CpG island of the RUNX3 gene is frequently hyper-
methylated in gastric cancer [41]. In this study, the CpG
island of the RUNX3 gene was specifically methylated in
the LOH-B gastric cancers (figure 5), which were associ-
ated with diffuse-type cancers without forming well-
defined glandular structures (table 4). The 5'-transitional
CpGs of genes other than RUNX3 were more frequently
hypomethylated in the LOH-B cases than in the LOH-L
and MSI cases (figure 6C). The RUNX3 gene plays a key
role in controlling many of the genes associated with the
differentiation of gastric epithelial cells [42]. The hyper-
methylated CpG island of the RUNX3  gene might be
responsible for extensive gene inactivation in gastric epi-
thelial cells developing into diffuse-type cancers. Accord-
ingly, silencing of such master genes should cause
widespread alterations in the intronic retroelement tran-
scripts and increase the hypomethylation changes in the
transitional area.
The CpG island of the MLH1 gene was specifically hyper-
methylated in the MSI cases, in which the hypermethyla-
tion of the 5'-transitional CpGs was most frequent (figure
6D). This is in agreement with previous studies reporting
that the MSI-positive gastrointestinal cancers accompany
the frequent hypermethylation of CpG islands [38,43].
MSI-associated hypermethylation is frequently observed
in the intestinal metaplasia and adenoma [36,39], and the
MSI cases has been reported to have a favourable clinical
outcome even in large-sized tumors [6,27]. In this study,
the 5'-transitional CpGs were infrequently hypermethyl-
ated in gastric cancers with a lymphatic and venous inva-
sion and an advanced stage (table 6). It is likely that
hypermethylation of the transitional CpGs can play more
of a role in the initiation of a gastric cancer [44], rather
than its progression.
Conclusion
A dosage compensation mechanism is believed to main-
tain a balance in the dose of L1 elements, which initiate
the long-distance spread of methylation involving the
genome-wide as well as transitional CpGs. The transi-
tional methylated CpG sites not completely protected by
the  Alu  elements were hypomethylated in association
with LOH events in gastric cancers. This suggests that an
irreversible unbalanced decrease in the genomic dose
reduces the spread of L1 methylation in the 5'-end regions
of genes in gastric cancers.BMC Cancer 2006, 6:180 http://www.biomedcentral.com/1471-2407/6/180
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